An evaluation of health-related quality of life and its relation with functional vision in children with cerebral visual impairment.

Background: Health-related Quality of Life (HRQOL) and its relation with functional vision is understudied in cerebral visual impairment (CVI).

Aims: Characterising HRQOL, comparing child self- and parent proxy-reports, and exploring relations with functional vision.

Methods And Procedures: Seventy-three children with CVI (n females = 33; n males = 40; Mean performance age = 7y2m) were included.

Presidents and vaccines: head of state inoculation as a tool for vaccine promotion.

Introduction: Vaccine hesitancy, an important threat to global health, has increased since the onset of the COVID-19 pandemic. The public vaccination of high-profile figures, such as heads of state, has been touted as a potential tool for increasing vaccine acceptance among the general population. However, systematic information on such role modelling is lacking and existing studies focus on a small number of high-income countries.

The volatilome reveals microcystin concentration, microbial composition, and oxidative stress in a critical Oregon freshwater lake.

Harmful algal blooms are among the most significant threats to drinking water safety. Blooms dominated by cyanobacteria can produce potentially harmful toxins and, despite intensive research, toxin production remains unpredictable. We measured gaseous molecules in Upper Klamath Lake, Oregon, over 2 years and used them to predict the presence and concentration of the cyanotoxin, microcystin, and microbial community composition.

Optimization of extraction methods for quantification of microcystin-LR and microcystin-RR in fish, vegetable, and soil matrices using UPLC-MS/MS.

Human-driven environmental change has increased the occurrence of harmful cyanobacteria blooms in aquatic ecosystems. Concomitantly, exposure to microcystin (MC), a cyanobacterial toxin that can accumulate in animals, edible plants, and agricultural soils, has become a growing public health concern. For accurate estimation of health risks and timely monitoring, availability of reliable detection methods is imperative.

[Pharmacology of tramadol].

(+/-)-Tramadol is a synthetic 4-phenyl-piperidine analogue of codeine. It is a central analgesic with a low affinity for opioid receptors. Its selectivity for mu receptors has recently been demonstrated, and the M1 metabolite of tramadol, produced by liver O-demethylation, shows a higher affinity for opioid receptors than the parent drug.

Contribution of monoaminergic modulation to the analgesic effect of tramadol.

1. In humans, the central analgesic effect of tramadol 100 mg orally is only partially reversed by the opioid antagonist naloxone (0.8 mg intravenously).

[Which analgesic dosage of paracetamol?].

The purpose of this study was to evaluate the dose-response of paracetamol and to assess its plasma concentration-effect relationship. According to a randomized, double-blind, and placebo controlled design healthy volunteers (n = 11) received 0.5, 1 and 2 g paracetamol (as propacetamol) intravenously (15 min).

The pharmacology of tramadol.

(+/-)-Tramadol is a central analgesic with low affinity for opioid receptors. The rate of production of its M1 metabolite (O-demethyl tramadol) is influenced by debrisoquine-type polymorphism, and this metabolite shows a higher affinity for opioid receptors than the parent drug. Experimental and clinical data suggest that tramadol may also exert its analgesic effect through direct modulation of central monaminergic pathways.

[Duality of the analgesic effect of tramadol in humans].

Tramadol is a central analgesic with low affinity for opioid receptors. A major active metabolite (O-desmethyl-tramadol) shows a higher affinity for opioid receptors than tramadol. The influence of naloxone and quinidine (a selective P450DB1 or CAP2D6 inhibitor) on tramadol effect was investigated crossover and double-blind vs placebo in healthy subjects.

Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates.

Data obtained from neonates receiving zidovudine as part of a phase I study were used to estimate the population pharmacokinetic parameters of this drug and to determine the minimum number of data points necessary to provide accurate estimates of the kinetic parameters and their variability. Analysis was performed with 541 concentrations of zidovudine, obtained from 32 infants and with a variety of reduced data sets using NONMEM (nonlinear mixed effect model). The reduced data sets were derived by randomly reducing the number of sampling time points per dosing interval and/or by randomly reducing the number of available subjects.

Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation.

We evaluated the effects of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics of gentamicin in 18 infants who underwent ECMO therapy for severe respiratory failure and received gentamicin for possible sepsis. Twelve of these infants continued to receive gentamicin after ECMO had been discontinued. The volume of distribution (Vd) of gentamicin in the newborns receiving ECMO was 0.